The Valley Desk

NCT03976375 · Interventional trial

Efficacy and Safety of Pembrolizumab (MK-3475) With Lenvatinib (E7080/MK-7902) vs. Docetaxel in Participants With Metastatic Non-Small Cell Lung Cancer (NSCLC) and Progressive Disease (PD) After Platinum Doublet Chemotherapy and Immunotherapy (MK-7902-008/E7080-G000-316/LEAP-008)

Overall registry status Completed

Phase 3

Conditions Metastatic Non-Small Cell Lung Cancer

Delaware Valley sites

First posted

Registry updated

Added to the directory

View this study on ClinicalTrials.gov